BOC vs PHOE

Boston Omaha Corporation (BOC) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 2/9, indicating weak operational and financial health. The company reports negative profitability across all key metrics—ROE, ROA, and profit margin—while its earnings have consistently missed estimates, with an average surprise of -383.33% over the last four quarters. Despite a low Price/Book ratio of 0.72 and a relatively healthy current ratio of 2.07, the absence of a meaningful Altman Z-Score and persistent losses raise serious concerns about long-term solvency. The stock trades at a 52-week discount but remains underperforming, with a 5-year decline of 66%, reflecting deep market skepticism. The lack of analyst coverage and neutral insider activity further diminish conviction.

PHOE exhibits a stable financial health profile with a Piotroski F-Score of 5/9 and a debt-free balance sheet, but it is fundamentally decoupled from its valuation. The stock trades at an astronomical P/E of 586.67 and a Price/Book of 50.72, while the Graham Number ($0.48) and Intrinsic Value ($0.21) suggest the current price of $17.60 is an extreme speculative premium. With revenue declining by 7.3% and earnings crashing by 76.1% YoY, there is no fundamental growth driver to justify the current market price.